TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01451606
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To serve as placebo for duloxetine. Administration schedule same as for active drug.
Study: NCT02718898
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00039104
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT00515021
Drug: Eplerenone (Morning)
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks followed by 4 weeks at 100mg.~100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 100mg, by mouth, daily, in the evening x another 4 weeks.
Study: NCT00515021
Drug: Eplerenone (Night-time)
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eplerenone - 50mg, by mouth, daily in the evening x 2 weeks followed by 4 weeks at 100mg
Study: NCT01446159
Drug: MEDI-573
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of MEDI-573 (10 or 30 or 45 mg/kg) will be administered on Day 1 of each 21-day cycle until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
Study: NCT01446159
Drug: Aromatase Inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor of the investigator's choice (letrozole, anastrozole, or exemestane) will be provided orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
Study: NCT03710187
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 50 mg IV Q6h
Study: NCT00298012
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00627393
Drug: Standard antimicrobial therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy is broadly defined as therapy within the standard of care for a particular infection and should be consistent within a given institution. Participants will undergo the recommended therapy for specific infections for 42 days.
Study: NCT03337308
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet or capsule to match bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or bempedoic acid 180 mg tablet, or ezetimibe 10 mg capsule
Study: NCT01794429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneum injection of placebo once-weekly for 3 months
Study: NCT01066637
Drug: [18F](+/-)NOS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of radiotracer \[18F\](+/-)NOS for PET imaging and kinetic data analysis
Study: NCT03527927
Drug: Any LABA/LAMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following consent, patients will be taken off their current ICS/LABA/LAMA combination inhalers and shown 4 single inhaler LABA/LAMA devices and asked to choose a preferred device to use, provided they can demonstrate effective use.
Study: NCT00397527
Drug: lactoserum
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00171964
Drug: Zoledronic acid in combination with therapy
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00182364
Drug: Fragmin (Dalteparin) LMWH verus Unfractionated Heparin (UFH)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03210558
Drug: Testosterone cream 1% (Andro-Feme® )
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone cream 10 mg (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.
Study: NCT03210558
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.
Study: NCT02246530
Drug: Subacromial steroid bursal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination steroid (Celestone) and anesthetic drug (Lidocaine) will be injected into the patient's subacromial bursa via needle guidance of ultrasound
Study: NCT01906489
Drug: AKB-6548
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Study: NCT01906489
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Study: NCT00236223
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT04094285
Drug: SAUERSTOFF
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAUERSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~min. 95.5%, breathing for 30 minutes
Study: NCT02129192
Drug: T80/H12.5 mg FDC tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg FDC tablet
Study: NCT02129192
Drug: T80/A5/H12.5 mg FDC tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg FDC tablet
Study: NCT03433651
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take by mouth 5 grams a day of creatine monohydrate powder.
Study: NCT03433651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take by mouth 5 grams a day of placebo powder.
Study: NCT00788801
Drug: ABT-614
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PET scan with radiotracer only, PET scan with radiotracer and ABT-614 Low Dose or ABT-614 High Dose
Study: NCT00005800
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04678895
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone matched placebo capsule.
Study: NCT04435288
Drug: Week 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: At week 60 (final study visit of SPARTACUS Phase A), patients reaching sustained clinical remission (at week 48 and 60), will roll-over into SPARTACUS Phase B. All other patients will be discontinued and will be treated with standard-of-care medication (including TNFi, if in accordance with Belgian reimbursement criteria).
Study: NCT03006276
Drug: DFN-15 Active
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00495274
Drug: Formulation A
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation A represents the original formulation. SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing micronized drug substance. Formulation A will be administered in Part A.
Study: NCT00495274
Drug: Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation B will represent SB-649868 10 mg film coated tablet containing micronized drug substance (3 tablets to reach 30 mg), but contains additional surfactant. Formulation B will be administered in Part A.
Study: NCT00495274
Drug: Formulation D
Normalized name: Complete Formulation D3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation D will represent SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing nanomilled and spray dried powder. Formulation D will be administered in Part A.
Study: NCT00495274
Drug: Formulation G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation G will be the selected formulation of SB-649868 30 mg to be assessed in Part B. The formulation will be administered after a standard FDA High-Fat breakfast
Study: NCT00412360
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush on Days -3 and -2.
Study: NCT01897779
Drug: RPX7009
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
Study: NCT01897779
Drug: RPX2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
Study: NCT01897779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
Study: NCT04627233
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo group received normal saline in a same volume to match corresponding HEP-1 doses. Study drug was administered by qualified staff in research clinic settings; injections were given to abdominal sites on rotating basis, by anatomic quadrant.
Study: NCT04293562
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT
Study: NCT04293562
Drug: Therapeutic Hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IT
Study: NCT01302340
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
Study: NCT02253173
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02253173
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04364867
Drug: Pain Pump
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive an interscalene block with Ropivicaine 0.5% (20cc), and then a pain pump attached in the Post Anesthesia Care Unit infusing at 4cc/hr. The patient will go home with that device until it runs out.
Study: NCT01513460
Drug: NVA237 50µg once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI)
Study: NCT01513460
Drug: Flu/Sal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device
Study: NCT00195702
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered, subcutaneous injection of placebo (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
Study: NCT00277823
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00832663
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: receive placebo
Study: NCT00626106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered with either exemestane or fulvestrant
Study: NCT04084444
Drug: T8 tablet 0.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.
Study: NCT04084444
Drug: T8 tablet 1mg
Normalized name: T8 Keto Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.
Study: NCT04084444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blank control.
Study: NCT02937272
Drug: LY3200882
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02937272
Drug: LY3300054
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT01986166
Drug: MEHD7945A
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEHD7945A will be administered as IV infusion at a dose of 1100 mg q2w until disease progression or unacceptable toxicity.
Study: NCT00740116
Drug: 0.9% NaCl solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl solution; 0.15 ml/kg body weight added to 100 ml 0.9% NaCl solution. The volume is given intravenously immediate before skin incision at surgery.
Study: NCT00833872
Drug: LEO 22811
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-in-man
Study: NCT00833872
Drug: placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02581215
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFIRINOX:~* Oxaliplatin 85 mg/m2 over 2-4 hours~* Irinotecan 165 mg/m2 over 90 minutes~* 5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.
Study: NCT03472586
Drug: Embolization Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo immunoembolization
Study: NCT02241460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the Double-Blind Treatment Period, patients randomized to placebo will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg. During the Open-Label Treatment Period, the patient will receive four weeks of Promescent (active treatment) in one-week cycles: 30 mg, 50 mg, 70 mg, and patient's self-selected dose.
Study: NCT01567072
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment with Ibuprofen 600mg 3times a day in 7 days after Colles fracture diagnosis
Study: NCT01567072
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment with Ibuprofen 600mg 3 times daily in 3 days after´diagnosis - Colles fracture
Study: NCT01567072
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only placebo treatment instead of NSAID painkillers
Study: NCT01493024
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized to mimic escalating doses of experimental drug administered 3 times daily (tid) with meals.
Study: NCT03942029
Drug: LY3154207 Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as capsule
Study: NCT03942029
Drug: LY3154207 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as tablet
Study: NCT03942029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as tablet
Study: NCT04115020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral suspension
Study: NCT01432236
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules twice a day for 14 weeks
Study: NCT00214695
Drug: Experimental Peritoneal Dialysis Solution
Normalized name: DEXTROSE/PERITONEAL DIALYSIS SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01865110
Drug: R-CHOP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 8 cycles
Study: NCT01865110
Drug: R-CHOP / R-HAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) administered in 3 week cycles for 3 cycles R-HAD (rituximab, cytarabine, dexamethasone) administered in 3 week cycles for 4 cycles alternating
Study: NCT01659437
Drug: Streptomycin intramuscular injection
Normalized name: streptomycin Injection
DrugBank: Streptomycin (DB01082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily intramuscular drug injection
Study: NCT01730768
Drug: AQW051
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01730768
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04094662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets for oral administration
Study: NCT00104429
Drug: GW873140
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01823991
Drug: VitaBlue™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza.
Study: NCT01823991
Drug: Lovaza®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza.
Study: NCT03263767
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 14 mg/kg intravenous 2 days at Day - 6 and day -5
Study: NCT03263767
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg intravenous 2 days at day +3 and day +4
Study: NCT03263767
Drug: Thymoglobulin Injectable Product
Normalized name: Thymoglobulin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: At day -2 2.5 mg/kg for patients inclued after 14 dec 2020
Study: NCT04422652
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind placebo.
Study: NCT00551200
Drug: HPN-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be taking prescribed dose of Buphenyl® TID (not to exceed 20g/day) at least two weeks prior to enrollment. Subjects will take prescribed dose of Buphenyl® TID for first week of study, and then switch over to HPN-100 TID during a dose-escalation phase. The dose of HPN-100 will be increased and the dose of Buphenyl® will be decreased each week by 50 mg/kg until entire daily dose of phenylbutyrate is HPN-100. Target HPN-100 dose will contain the same amount of phenylbutyrate as the subject's prescribed daily dose of Buphenyl®. Subject will take HPN-100 alone for one week and then switch back to previous dose of Buphenyl for the last week of the study.
Study: NCT00551200
Drug: BUPHENYL®
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUPHENYL® (sodium phenylbutyrate) tablets and powder have been approved for marketing in the United States since 1996 as an adjunctive therapy in the long-term management of patients with UCDs involving deficiencies of CPS, OTC, or ASS.
Study: NCT03641417
Drug: GLWL-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small molecule inhibitor of Ghrelin-O-Acyltransferase (GOAT) to reduce levels of circulating acyl ghrelin.~(Defined as a mechanistic study by MHRA; intervention not for therapeutic purposes in this study.)
Study: NCT03322540
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered orally twice daily.
Study: NCT02408016
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01544296
Drug: KHK6188
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03466528
Drug: Pabrinex
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard treatment
Study: NCT00867594
Drug: ORMD 0801
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule ORMD 0801 3 times a day, before each meal
Study: NCT01544296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02558959
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01782898
Drug: Placebo Comparator: .9 normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator: Placebo .9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,
Study: NCT04879030
Drug: Beta-Lactams
Normalized name: BETA-LACTAMS ANTIMICROBIALS,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient was randomized to use beta-lactams antibiotic
Study: NCT04879030
Drug: Fluoroquinolone
Normalized name: Fluoroquinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient was indicated to use a combination of beta-lactams and fluoroquinolones
Study: NCT01910285
Drug: Remifentanyl - sufentanil placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction of general anesthesia with 3 mg/kg of propofol combined with 3 µg/kg of remifentanil and 10 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
Study: NCT01910285
Drug: Sufentanil - remifentanyl placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction of general anesthesia with 3 mg/kg of propofol combined with 0.3 mg/kg of sufentanil and 25 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
Study: NCT03622788
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02727803
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05638529
Drug: Pregnyl (1,500) IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will self-administer a subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of hCG (Pregnyl 1,500 IU) on their assigned trigger day.
Study: NCT05638529
Drug: 1.5 mL of normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will self-administer a subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of normal saline (1.5 mL - sham placebo) on their assigned trigger day.
Study: NCT02809963
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg tablets, oral use.
Study: NCT02809963
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tablets, oral use
Study: NCT03287960
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily subcutaneous injection